Kite Pharma (KITE) Highlights Publishing of Results Showing Durable Complete Remissions Up to 56+ Months in … – StreetInsider.com
|
Kite Pharma (KITE) Highlights Publishing of Results Showing Durable Complete Remissions Up to 56+ Months in …
StreetInsider.com Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, highlighted the recent online publication of results in Molecular Therapy from a National Cancer Institute (NCI) study of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in … |
